Johnson & Johnson’s New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner

All NewsFebruary 17, 2026

FDA approves monthly dosing for J&J’s Rybrevant Faspro with Lazcluze, offering faster, easier treatment for EGFR lung cancer.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent